Business

Novo says Wegovy injection lowers BMI and obesity rates in children in trial

CNBC November 16, 2026 2 views
Novo says Wegovy injection lowers BMI and obesity rates in children in trial

Advertisement

Novo Reports Success in Wegovy Trial for Child Obesity Treatment

Danish pharmaceutical company, Novo Nordisk, has announced promising results from a clinical trial testing the effectiveness of its obesity treatment, Wegovy, on children aged 10 to 11.

The trial, conducted on a small group of children, showed significant reductions in body mass index (BMI) and obesity rates after administering Wegovy injections. According to the company, "the treatment resulted in a 20% reduction in BMI and a 25% reduction in obesity rates."

Currently, Wegovy is approved for use in children aged 12 and older to treat obesity. However, the new trial findings suggest that the medication could potentially address the growing issue of childhood obesity in younger age groups as well.

"The findings from this trial are a positive step towards providing effective treatment options for children affected by obesity," said Dr. Jan Skovlund, Chief Medical Officer of Novo Nordisk.

Skovlund emphasized the importance of addressing childhood obesity at an early stage, stating, "Early intervention is crucial in preventing long-term health complications associated with obesity."

Novo Nordisk plans to continue evaluating the trial results and is expected to submit the findings for review by regulatory authorities in the coming months. If approved, Wegovy could become the first medication specifically designed to treat childhood obesity in children under 12.

In the meantime, parents and healthcare providers are advised to consult with medical professionals regarding potential treatment options for young children suffering from obesity.

Novo Nordisk Reports Success in Wegovy Trial for Childhood Obesity Treatment

  • Danish pharmaceutical company, Novo Nordisk, has announced promising results from a clinical trial testing the effectiveness of its obesity treatment, Wegovy, on children aged 10 to 11.
  • The trial showed a 20% reduction in BMI and a 25% reduction in obesity rates after administering Wegovy injections.
  • Currently, Wegovy is approved for use in children aged 12 and older to treat obesity.
  • Novo Nordisk plans to continue evaluating the trial results and submit the findings for review by regulatory authorities in the coming months.
  • If approved, Wegovy could become the first medication specifically designed to treat childhood obesity in children under 12.

The trial involved a small group of children, with Dr. Jan Skovlund, Chief Medical Officer of Novo Nordisk, stating, "The findings from this trial are a positive step towards providing effective treatment options for young children suffering from obesity.

Skovlund emphasized the importance of addressing childhood obesity at an early stage, saying, "Early intervention is crucial in preventing long-term health complications associated with obesity.

Novo Nordisk will continue to analyze the trial results and submit them for review by regulatory authorities in the coming months. If approved, Wegovy could become the first medication specifically designed to treat childhood obesity in children under 12.

Parents and healthcare providers are advised to consult with medical professionals regarding potential treatment options for young children suffering from obesity.

Novo Nordisk Reports Promising Trial Results for Childhood Obesity Treatment

  • Danish pharmaceutical company, Novo Nordisk, has announced positive trial results for its obesity treatment, Wegovy, in children aged 10 to 11.
  • The trial involved a small group of children, with Dr. Jan Skovlund, Chief Medical Officer of Novo Nordisk, stating, "The findings from this trial are a positive step towards providing effective treatment options for young children suffering from obesity.
  • Skovlund emphasized the importance of addressing childhood obesity at an early stage, saying, "Early intervention is crucial in preventing long-term health complications associated with obesity.
  • Novo Nordisk will continue to analyze the trial results and submit them for review by regulatory authorities in the coming months.
  • If approved, Wegovy could become the first medication specifically designed to treat childhood obesity in children under 12.
  • Parents and healthcare providers are advised to consult with medical professionals regarding potential treatment options for young children suffering from obesity.

<small>Source: CNBC — read the original story there.</small>

How did this make you feel?

Never miss a story

Get the best of SpeakOX in your inbox. No spam, unsubscribe anytime.

Advertisement

Category
Business

Advertisement